Revenue
2024
2025
CytoMed Therapeutics Ltd (GDTC)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $324,387 | $69,501 | — | — | — | — |
| Research & development | $2.2M | $1.9M | $1.6M | $1.5M | $1.1M | $1.0M |
| Net income | −$4.0M | −$2.5M | −$4.1M | −$3.1M | −$2.1M | −$1.9M |
| Basic EPSper diluted share | -SGD 0.34 | -SGD 0.22 | -SGD 0.39 | -SGD 0.40 | -SGD 0.30 | — |
| Diluted EPSper diluted share | -SGD 0.34 | -SGD 0.22 | -SGD 0.39 | -SGD 0.40 | -SGD 0.30 | -SGD 0.33 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 13, 2026Form 4 | Choo Chee KongDirector,TenPercentOwner | BuyOrdinary Shares, no par value per share | 112.0K | $1.15 | $128.8K | 430.3K |